Royalty Pharma acquires Nuvalent cancer drug royalties in $315 million deal
NEW YORK – Royalty Pharma plc said on Tuesday it acquired a royalty interest in two of Nuvalent Inc’s experimental lung cancer therapies for up to $315 million, betting on the drugs’ multi-billion dollar sales potential. The deal gives the…